NCT06926868: An ongoing trial by Bristol-Myers Squibb
This trial is ongoing. It must report results 2 years, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06926868 |
|---|---|
| Title | IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 11, 2025 |
| Completion date | March 13, 2028 |
| Required reporting date | March 13, 2029, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |